Advertisement
Research Article

Characteristics and Impact of Drug Detailing for Gabapentin

  • Michael A Steinman mail,

    To whom correspondence should be addressed. E-mail: mike.steinman@ucsf.edu

    Affiliations: San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America, Division of Geriatrics, University of California, San Francisco, California, United States of America

    X
  • G. Michael Harper,

    Affiliations: San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America, Division of Geriatrics, University of California, San Francisco, California, United States of America

    X
  • Mary-Margaret Chren,

    Affiliations: San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America, Department of Dermatology, University of California, San Francisco, California, United States of America

    X
  • C. Seth Landefeld,

    Affiliations: San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America, Division of Geriatrics, University of California, San Francisco, California, United States of America

    X
  • Lisa A Bero

    Affiliations: Department of Clinical Pharmacy, University of California, San Francisco, California, United States of America, Institute for Health Policy Studies, University of California, San Francisco, California, United States of America

    X
  • Published: April 24, 2007
  • DOI: 10.1371/journal.pmed.0040134

About the Authors

Michael A Steinman, G. Michael Harper, Mary-Margaret Chren, C. Seth Landefeld
San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America
Michael A Steinman, G. Michael Harper, C. Seth Landefeld
Division of Geriatrics, University of California, San Francisco, California, United States of America
Mary-Margaret Chren
Department of Dermatology, University of California, San Francisco, California, United States of America
Lisa A Bero
Department of Clinical Pharmacy, University of California, San Francisco, California, United States of America
Lisa A Bero
Institute for Health Policy Studies, University of California, San Francisco, California, United States of America

Corresponding Author

Email: mike.steinman@ucsf.edu

Competing Interests

MAS, MMC, and CSL served as unpaid expert witnesses for the plaintiff in the litigation from which source data for this report was obtained (United States of America ex rel. David Franklin v. Pfizer, Inc. and Parke-Davis, Division of Warner-Lambert Company). GMH and LAB were not involved in this litigation. MAS is a member of the board of No Free Lunch. He does not receive any compensation for this position and No Free Lunch had no role in the preparation or submission of this manuscript. Seed funding for an online searchable archive of documents from the gabapentin litigation (http://dida.library.ucsf.edu) was provided by a gift from Thomas Greene, lawyer for the whistleblower plaintiff in this litigation, to the University of California Board of Regents. Two of the authors (MAS, CSL) participated in the creation and development of the archive, including solicitation of start-up funding from Mr. Greene. The cost of obtaining and photocopying some of the documents used in this research was paid by the archive, which incorporated these documents into the collection. The authors have no financial conflict of interest with any product discussed in this manuscript.

Author Contributions

MAS developed the research question, obtained and coded the data, conducted the analyses, and wrote the paper. GMH, MMC, CSL, and LAB assisted in the development of the analytic plan and interpretation of the findings, and critically reviewed successive drafts of the manuscript. GMH and LAB also assisted in coding of the data.